A
AMRX
Amneal Pharmaceuticals Inc
12.54
-0.26-2.03%After Hours: 12.56 +0.02 +0.16%16:44 04/10 EDT
OPEN/PREV CLOSE12.84/12.80
TODAY RANGE12.40-12.88
VOL1.47M
MARKET CAP4.00B
52 WEEK RANGE6.69-15.42
AVG VOL (3M)2.61M
% TURNOVER0.46%
TURNOVER--
P/E (TTM)56.54
% RANGE3.72%
EPS(TTM)0.2218
P/E(FORWARD)50.16
P/B-55.7086
BVPS-0.2251
DIVIDEND--
P/S1.307
BETA--
DIV YIELD0.00%
FREE FLOAT MKT CAP2.08B
SHARES OUTSTANDING319.00M
NEXT EARNINGS04/30-05/04
FREE FLOAT166.18M
LOT SIZE1
EX-DATE--
News
Press Releases
Financial Reports
Profile
Simply Wall St·10h ago
Should Amneal’s New Generic Glaucoma Launch Shape How AMRX Investors View Its Specialty Strategy?
Simply Wall St·1d ago
Is It Time To Reassess Amneal Pharmaceuticals (AMRX) After Its Strong Multi Year Share Price Run?
Reuters·03/24 20:25
AMNEAL PHARMA: NOT RECEIVED ANY ADVERSE EVENT REPORTS RELATED TO THIS RECALL
Simply Wall St·03/20 02:08
How Amneal’s Margin-Focused 2026 Outlook and 2025 Results Could Impact Amneal Pharmaceuticals (AMRX) Investors
Simply Wall St·03/19 01:11
A Look At Amneal Pharmaceuticals (AMRX) Valuation After Strong 2025 Results And 2026 Growth Guidance
TipRanks·03/18 07:36
Barclays Sticks to Their Buy Rating for Amneal Pharmaceuticals (AMRX)
Seeking Alpha·03/16 19:09
Amneal Pharmaceuticals: Flattish 2026 Revenue Growth Aside, Stock Still Looks A Buy
Simply Wall St·03/11 05:15
What Amneal Pharmaceuticals (AMRX)'s Return to Profitability and 2026 Guidance Means For Shareholders
Simply Wall St·03/10 00:27
Reassessing Amneal Pharmaceuticals (AMRX) Valuation After Strong Long Term Returns And A High Current P/E Ratio
NASDAQ·03/09 12:22
New Strong Buy Stocks for March 9th